Sanofi (SNY) and Principia Biopharma (PRNB) $3.68bn acquisition information including expected completion date, offer price and contact details are displayed in the acquisition details table below. An invaluable buyout factsheet for traders and investors looking to trade the merger arbitrage spread.
This deal was successfully consummated on September 25, 2020
| Acquisition Details | Value |
|---|---|
| Acquisition Target Stock Name | Principia Biopharma |
| Acquisition Target Stock Ticker | PRNB |
| Acquirer Name and Ticker | Sanofi (SNY) |
| Announcement Date | August 17, 2020 |
Principia Biopharma (PRNB) Acquisition
Receive FREE instant access to constantly updated PRNB news related to the current acquisition. Simply register by entering your email address to receive weekly publication updates. For more proprietary Merger Arbitrage Limited content and analysis on this buyout, click Principia Biopharma (PRNB). Proprietary commentary can also be accessed by simply entering a ticker symbol into the search box such as “PRNB“, or clicking on a stock ticker in the tag cloud at the foot of this article.
Traders and shareholders can review similar acquisition details on current takeover stocks by first selecting “DEALS” from the main menu above, then “Current Cash Deals” or “Current Stock Deals“. For previous acquisitions, select either “Closed Deals” or “Failed Deals“. See our Spread Tracker News for mergers and acquisitions updates on the existing T20 Index portfolio constituents. Additionally, check out our customized M&A PR Newswire or Business Wire press release news feeds exclusively for Merger Arbitrage Limited.
Principia Biopharma (NASDAQ: PRNB) Acquisition - Merger News and Events
The major acquisition news updates & events of Principia Biopharma (PRNB) by Sanofi (SNY) are listed below. A comprehensive data source for
- Traders looking to familiarize themselves with the Sanofi (SNY) buyout of Principia Biopharma (PRNB) and trade the merger arbitrage spread
- Existing shareholders and investors wishing to stay abreast of the latest deal developments.
Following the acquisition news section, there is an in-depth company profile.
Principia Biopharma Company Profile
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immune-mediated diseases. The company is developing rilzabrutinib, an inhibitor that is in Phase III clinical trials for the treatment of pemphigus, a chronic skin disease, as well as and pemphigus foliaceus; in a Phase 1/2 trial for the treatment of immune thrombocytopenia; and a Phase 2 trial for the treatment of IgG4-related disease.
It is also developing PRN2246/SAR442168, an inhibitor, which is in Phase Ii clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; and PRN473, a drug candidate that is in Phase I clinical trial for the treatment of immune-medicated diseases. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
